| __timestamp | CRISPR Therapeutics AG | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 4932500000 |
| Thursday, January 1, 2015 | 12573000 | 5037200000 |
| Friday, January 1, 2016 | 42238000 | 5654900000 |
| Sunday, January 1, 2017 | 69800000 | 6070200000 |
| Monday, January 1, 2018 | 113773000 | 4681700000 |
| Tuesday, January 1, 2019 | 179362000 | 4721200000 |
| Wednesday, January 1, 2020 | 269407000 | 5483300000 |
| Friday, January 1, 2021 | 17953000 | 7312800000 |
| Saturday, January 1, 2022 | 110250000 | 6629800000 |
| Sunday, January 1, 2023 | 130250000 | 7082200000 |
| Monday, January 1, 2024 | -2314000 | 8418299999 |
Data in motion
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. Eli Lilly and Company, a stalwart in the pharmaceutical industry, has consistently maintained a high cost of revenue, averaging around $5.76 billion annually from 2014 to 2023. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, has seen its cost of revenue grow from a modest $1.5 million in 2014 to approximately $130 million in 2023, marking an impressive increase of over 8,500%.
While Eli Lilly's cost of revenue peaked in 2021 at $7.31 billion, CRISPR Therapeutics experienced its highest cost in 2020, reaching $269 million. This divergence highlights the different growth trajectories and operational scales of these companies. As the biotech sector continues to innovate, monitoring these financial trends offers valuable insights into the industry's future.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Johnson & Johnson
Cost of Revenue Comparison: Eli Lilly and Company vs Biogen Inc.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Viatris Inc.
Cost Insights: Breaking Down Eli Lilly and Company and Telix Pharmaceuticals Limited's Expenses
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Cost Insights: Breaking Down Eli Lilly and Company and Geron Corporation's Expenses
Cost Insights: Breaking Down Biogen Inc. and CRISPR Therapeutics AG's Expenses
Analyzing Cost of Revenue: Viatris Inc. and CRISPR Therapeutics AG
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Analyzing Cost of Revenue: CRISPR Therapeutics AG and Geron Corporation